A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ENC1018 for SADDrug: Placebo for SADDrug: ENC1018 for MADDrug: Placebo for MAD
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- EnnovaBio Australia Pharmaceuticals Pty Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06224400
- Locations
- 🇦🇺
Nucleus Network Pty Ltd., Melbourne, Victoria, Australia
A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: ENN0403 4mgDrug: ENN0403 10mgDrug: ENN0403 1mgDrug: ENN0403 12mg QD X 14 DaysDrug: ENN0403 20mg QD X 14 DaysDrug: ENN0403 20mgDrug: ENN0403 30mgDrug: ENN0403 20mg (Fed)Drug: ENN0403 6mg QD X 14 DaysDrug: Placebo
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- EnnovaBio Australia Pharmaceuticals Pty Ltd
- Target Recruit Count
- 69
- Registration Number
- NCT05506540
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, Australia
© Copyright 2025. All Rights Reserved by MedPath